Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Author(s): Koichi Goto, MD, PhD1; Yasushi Goto, MD, PhD2; Toshio Kubo, MD, PhD3; Kiichiro Ninomiya, MD, PhD4; Sang-We Kim, MD, PhD5; David Planchard, MD, PhD6; Myung-Ju Ahn, MD, PhD7; Egbert F. Smit, MD, PhD8; Adrianus Johannes de Langen, MD, PhD9; Maurice Pérol, MD10; Elvire Pons-Tostivint, MD, PhD11; Silvia Novello, MD, PhD12; Hidetoshi Hayashi, MD, PhD13; Junichi Shimizu, MD, PhD14; Dong-Wan Kim, MD, PhD15; Chih-Hsi Kuo, MD, PhD16; James Chih-Hsin Yang, MD, PhD17; Kaline Pereira, MD, PhD18; Fu-Chih Cheng, PhD18; Ayumi Taguchi, PharmD19; Yingkai Cheng, MD, PhD18; Wenqin Feng, PhD18; Zenta Tsuchihashi, PhD18; and Pasi A. Jänne, MD, PhD20
Source: DOI: 10.1200/JCO.23.01361 Journal of Clinical Oncology 41, no. 31 (November 01, 2023) 4852-4863.
Anjan J Patel MD

Dr. Anjan Patel's Thoughts

Preliminary results of DESTINY-Lung02 show strong efficacy with trastuzumab deruxtecan (T-DXd). Overall response rate (ORR) was about 50%, with duration of response of 16.8 months.

This is now FDA-approved and is an available therapy for patients with ERBB2 mutations after 1st line platinum-based chemo +/- immunotherapy. This is preferred over traditional trastuzumab or afatinib. Interestingly, some responses were seen in the ERBB2-negative patients who had over-expression by IHC. Please continue to sequence your patients and enroll in targeted therapy trials.


Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2–mutant (HER2m; defined as single-nucleotide variants and exon 20 insertions) metastatic non–small-cell lung cancer (mNSCLC).


DESTINY-Lung02, a blinded, multicenter, phase II study, investigated T-DXd 5.4 mg/kg once every 3 weeks for the first time in previously treated (platinum-containing therapy) patients with HER2m mNSCLC and further assessed T-DXd 6.4 mg/kg once every 3 weeks in this population. The primary end point was confirmed objective response rate (ORR) per RECIST v1.1 by blinded independent central review.


One hundred fifty-two patients were randomly assigned 2:1 to T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. As of December 23, 2022, the median duration of follow-up was 11.5 months (range, 1.1-20.6) with 5.4 mg/kg and 11.8 months (range, 0.6-21.0) with 6.4 mg/kg. Confirmed ORR was 49.0% (95% CI, 39.0 to 59.1) and 56.0% (95% CI, 41.3 to 70.0) and median duration of response was 16.8 months (95% CI, 6.4 to not estimable [NE]) and NE (95% CI, 8.3 to NE) with 5.4 and 6.4 mg/kg, respectively. Median treatment duration was 7.7 months (range, 0.7-20.8) with 5.4 mg/kg and 8.3 months (range, 0.7-20.3) with 6.4 mg/kg. Grade ≥ 3 drug-related treatment-emergent adverse events occurred in 39 of 101 (38.6%) and 29 of 50 (58.0%) patients with 5.4 and 6.4 mg/kg, respectively. 13 of 101 (12.9%) and 14 of 50 (28.0%) patients had adjudicated drug-related interstitial lung disease (2.0% grade ≥ 3 in each arm) with 5.4 and 6.4 mg/kg, respectively.


T-DXd demonstrated clinically meaningful responses at both doses. Safety profile was acceptable and generally manageable, favoring T-DXd 5.4 mg/kg.

Author Affiliations

1National Cancer Center Hospital East, Kashiwa, Japan; 2National Cancer Center Hospital, Tokyo, Japan; 3Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan; 4Okayama University Hospital, Okayama, Japan; 5Asan Medical Center, Seoul, Republic of Korea; 6Gustave Roussy, Department of Medical Oncology, Thoracic Group, Villejuif, France; 7Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 8Leiden University Medical Center, Leiden, the Netherlands; 9Netherlands Cancer Institute, Amsterdam, the Netherlands; 10Léon Bérard Center, Lyon, France; 11Centre Hospitalier Universitaire Nantes, Nantes University, Nantes, France; 12Department of Oncology, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, University of Turin, Turin, Italy; 13Kindai University Hospital, Osaka, Japan; 14Aichi Cancer Center Hospital, Aichi, Japan; 15Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea; 16Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan; 17National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan; 18Daiichi Sankyo Inc, Basking Ridge, NJ; 19Daiichi Sankyo, Tokyo, Japan; 20Dana-Farber Cancer Institute, Boston, MA

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Perioperative Nivolumab in Resectable Lung Cancer

Perioperative nivolumab (Nivo) showed a 20% 18-month EFPS improvement. This is another option to consider for your patients with stage IIA-IIIB NSCLC. Of note, the study arm received chemo + Nivo x 4 cycles preoperatively, then 12 months of Nivo therapy, and toxicities were as expected.

Read More »

Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer

FCS medical oncologist and hematologist Ernesto Bustinza-Linares, MD has co-authored an abstract published in the American Society of Clinical Oncology Journal, JCO Precision Oncology, that uncovers a new testing method to determine personalized care options for patients with metastatic non-small cell lung cancer (NSCLC). The abstract’s authors address the limitations of existing guidelines that recommend checkpoint immunotherapy, sometimes in combination with chemotherapy, for treating NSCLC, which often discounts patient variability and immune factors. The findings from the study show that by incorporating additional plasma proteome-based testing, combined with the standard protein inhibitor testing, clear differences in patient outcomes were observed after applying targeted treatments based on the testing results.

Read More »

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Adding VEGF inhibitor to PD-1 blocker in addition to chemotherapy is better than a chemotherapy-alone regimen as a second-line therapy after TKI failure. This is true especially in patients with tumors with high PD-L1 expression, with not much besides chemotherapy as second-line therapy for those patients (or other clinical trials) that may be a better option that includes immunotherapy.

Read More »

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

This is the same issue as the Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) article, this one was negative though. A question for the previous trial would be: do we need PDL-1 inhibitor, or just VEGF inhibitor, recall the pts with tumors with high PDL-1 expression did better though, so most likely we need both with chemotherapy.

Read More »